SOURCE: Anoto Group AB

March 20, 2007 09:00 ET

Anoto Group's Digital Pen and Paper Technology Gains Global Market Attention in Healthcare

22nd Annual DIA Presenter Dr. Massimo Raineri, PhD of Actelion Pharmaceuticals Ltd. Illustrates How Anoto Digital Pen and Paper Technology Improves Clinical Trials

BOSTON, MA -- (MARKET WIRE) -- March 20, 2007 -- Anoto, the inventor of Digital Pen and Paper technology, announces today its leadership position in providing unique data collection and Digital Pen and Paper technology to support the data collection processes within clinical trials. Actelion Pharmaceuticals will present its unique application of Digital Pen and Paper technology on March 20 (Track 3 - Technology, 10:30-12pm) at the 22nd Annual DIA Clinical Data Management Conference and Exhibition being held in Orlando, Florida.

Dr. Massimo Raineri, PhD of Actelion will illustrate how Digital Pen and Paper applications developed in collaboration with Actelion and Anoto partners and digital writing solution developers GM Servizi and Kayentis, could help to accelerate the development of new drugs by making trial processes more efficient and accurate.

"Cutting the time to submit an NDA by a few months has evident advantages both from the point of view of the patients, who can profit earlier of potentially life-saving treatments, as well as from the financial point of view; in clinical development every day you save can be worth millions of dollars," said Dr. Massimo Raineri, PhD, Actelion Pharmaceuticals.

The Digital Pen and Paper technology has been widely and quickly embraced not only in clinical trials but the entire health care sector because it provides such an easy and straight-forward way to capture handwritten text and quickly transmit it from paper to digital formats. Clinical trial investigators save time by being able to concentrate on their research work without being burdened by learning new system interfaces for data collection and document management.

"We are very pleased to be acknowledged as a leader in Digital Pen and Paper data collection technology as evidenced by the growing number of hospitals and nursing homes that are implementing solutions based on our technology. In particular to DIA, we consider Actelion's use of more than 500 digital pens in 12 clinical trials helps further demonstrate how useful our technology is proving to be," stated Lars Hermansen, EVP of Sales and Marketing at Anoto Group AB

For a typical clinical trial application, Anoto's Digital Pen and Paper technology helps organizations capture, validate, integrate and process clinical research data using Case Report Forms (CRFs) that have been printed with a unique, nearly invisible dot pattern to ensure complete traceability and data collection accuracy.

"Clin'Form, our set of products and services based on Digital Pen and Paper represent a significant opportunity to streamline and improve the CRF data handling in clinical trials, where the practical and legal advantage of paper records continues to be high in spite of the attempts to substitute paper forms with various kinds of Electronic Data Capture (EDC) systems. 3000 active users in 20 countries and 5 continents take advantage of them today. Among these, we are pleased to deliver support and printing services to Actelion Pharmaceuticals," stated Eric Rueda, Head of Pharma/Healthcare at Kayentis.

Pharmaceutical and bio-tech sectors are experiencing explosive growth due to the demands of the baby boomer generation reaching retirement age, and there is now, more than ever before, the impetus to quickly create, test, and make available life extending drugs and procedures.

About Anoto Group

Anoto Group AB is the inventor of Digital Pen and Paper technology that allows quick and highly reliable transmission of handwritten text from paper to digital media. Anoto works with a global network of partners in developing user-friendly forms solutions for efficient capture, transmission and storage of data for a variety of business segments including healthcare, banking and finance, transportation and logistics, government and education. Anoto's goal is to make the collection and processing of data more efficient, accurate, and cost effective while keeping the process as familiar and natural as possible for the user through the universal experience of pen and paper. Founded in 1999, the Anoto Group's European corporate office is in Lund, Sweden. Its US corporate office is in Boston, MA and Asian corporate office is located in Tokyo, Japan. Major shareholders are Norden Technology A/S, Logitech International S/A, Robur and DNB. The Anoto share is traded on the Nordic Mid Cap list of the Stockholm Stock Exchange under the ticker ANOT (STKM: ANOT). For more information please visit www.anoto.com.

About GM Servizi

GM Servizi is a software house producing application systems based on the Web. They are mainly focused in building solutions for the Facility Management and Clinical Research markets and supply their customers with full systems ready for digital pen data collection and management, or integration services of the Anoto technology in existing systems. For more info visit www.inkdata.eu

About Kayentis

Kayentis is a leading integrator and operator of digital writing professional solutions specialized in Healthcare and Life Science, Manufacturing and Services sectors. Kayentis' range of services improves key company process performance. Data collected by physicians, nurses, technicians and clerks in demanding environments such as healthcare are subject to strict levels of security and traceability. The solutions are built on top of Forms Automation System, an industry standard platform, proven and answering the daily needs of thousands of pen users when it comes to print on demand, unique pattern and secured data exchanges. For more info visit www.kayentis.fr.

Contact Information

  • Media Contacts:

    Valerie Harding
    Ripple Effect Communications
    Main Tel: 617-536-8887
    Email: Email Contact

    Maria Galvin
    Corporate Communications Manager
    Anoto Group AB
    Tel: +46 46 540 10 21
    Email: Email Contact